ShareThis Page

McCandless woman 1st in region with implant aimed at halting seizures

| Saturday, Aug. 1, 2015, 10:16 p.m.
Jasmine Goldband | Trib Total Media
Georgette Nichols, 46, of McCandless uses a wand to scan the RNS Neurostimulator, or RNS system, that is implanted in her skull. Information from the device, which helps control her epilepsy, is uploaded each week to a server for her doctors to analyze.
Jasmine Goldband | Trib Total Media
Georgette Nichols, 46, of McCandless uses a wand to scan the RNS Neurostimulator, or RNS system, that is implanted in her skull. Information from the device, which helps control her epilepsy, is uploaded each week to a server for her doctors to analyze.
Jasmine Goldband | Trib Total Media
Georgette Nichols, 46, of McCandless says the device implanted in her skull to short-circuit her epileptic seizures has changed her life. Though she still takes medication, she's having fewer seizures, she says.
Jasmine Goldband | Trib Total Media
Georgette Nichols, 46, of McCandless meets with Alexandra Popescu, medical director of UPMC’s epilepsy surgery program, during an appointment in UPMC Montefiore in Oakland. Nichols in January became the first patient in Pittsburgh to receive an RNS device to help control her epileptic seizures.
Jasmine Goldband | Trib Total Media
Nancy Griffey of Erie works with Arun Antony, a University of Pittsburgh assistant professor of neurology, during an appointment at UPMC Montefiore in Oakland. Griffey's husband Jim (right), accompanied her. She is among the first UPMC Epilepsy Division patients to receive a brain implant to help control her epileptic seizures.

Each night before bed, Georgette Nichols brushes her teeth, washes her face and holds an electronic wand to her head to download brain wave activity from a computer chip embedded in her skull.

“No big deal,” Nichols, 46, of McCandless said with a laugh. “We all have our daily routines. This is now part of mine.”

For 34 years, Nichols endured unpredictable epileptic seizures that sometimes made her feel like an outcast.

“I'd be at work, and I'd just go into a trance and start staring,” said Nichols, a sales representative at JC Penney in Ross Park Mall. “When I'd come out of it, I always had a feeling of frustration. To be honest, I felt like a freak.”

The tiny device, which was surgically placed in Nichols' skull, is giving her newfound hope by sharply reducing the frequency and duration of her seizures. Known as the RNS Neurostimulator, or RNS system, the brain monitor sends bursts of electrical stimulation to halt oncoming seizures.

Nichols in January became the first patient in Pittsburgh to receive an RNS device in UPMC Presbyterian in Oakland. Since then, three more local patients have received the $50,000 treatment, which is offered in 81 medical centers across the country. Nationally, about 500 people have received implants, including those involved in clinical trials.

“This is the first time in the history of neurosurgery that we have a real brain-computer interface that can respond to a patient's brain activity,” said Dr. Mark Richardson, director of epilepsy and movement disorders surgery at UPMC. “It offers a lot of potential for us to learn more about epilepsy networks within the brain.”

About 3 million Americans have epilepsy, a chronic brain disorder that causes uncontrollable seizures, loss of consciousness, shaking and staring.

In most cases, direct causes of epilepsy are unknown.

Frank Fischer, CEO of the RNS device maker NeuroPace Inc., based in Mountain View, Calif., estimates that more than 500,000 Americans with epilepsy could be helped by the innovative treatment.

“The most impressive thing we've heard comes from patients or their family members thanking us for giving them their lives back,” Fischer said. “They're getting the opportunity to live the quality of life that they're entitled to.”

About 70 percent of implant recipients report at least 50 percent fewer seizures within six years, he said. However, an implantation does not necessarily mean patients can immediately discontinue their medicine. Nichols, for example, still takes three forms of anti-seizure medication.

17 years in development

The RNS system, approved by the Food and Drug Administration in 2013, was in development for 17 years.

Here's how it works: The battery-powered, programmable neurostimulator is implanted in a patient's skull, and leads or wires connected to electrodes are implanted in the brain area from which seizures originate. The technology is designed to short-circuit seizures by detecting abnormal brain-wave activity and delivering brief bursts of electrical stimulation through the electrodes to halt a seizure or shorten its duration.

Before FDA approval, clinical trials of the device showed a 38 percent reduction in seizure activity within several months for patients, according to Dr. Nathan Fountain, chairman of the advisory board of the Epilepsy Foundation in Landover, Md.

“The epilepsy community is excited about this because it's great technology. We're hoping we can use this to discover new things about epilepsy,” he said.

At the same time, doctors emphasize that they promote the approach not to cure seizures but to reduce them when medication is ineffective. The only certain epilepsy cure is targeted surgery to remove parts of the brain where seizures begin — an option unavailable to many patients, Fountain said.

The RNS option is not cheap, but it's generally covered by insurance companies. The device, along with equipment needed to download data, costs about $37,000, before surgery and diagnostic testing.

“It is expensive,” Fountain said, “but it's worthwhile if you're a patient who experiences a reduction in seizures.”

Proactive patients

Patients who receive the RNS device need to take an active role for true success. Besides wearing the device, they must upload data captured by the electronic wand to a server accessible by the doctor and NeuroPace engineers.

Patients transfer the data to a laptop and send it each week to doctors for detailed analysis. By doing so, “we can teach this little device how to properly detect the seizure signature,” said Dr. Alexandra Popescu, medical director of UPMC's epilepsy surgery program.

The data help doctors continually reset the RNS device to better combat seizures. In some patients, the process can take as long as two years for optimal benefits, Richardson said.

“Every person's seizure activity is very different,” he said. “But it's really exciting that we now have the opportunity to basically reprogram the device in ongoing fashion.”

Fischer estimated that just 10 percent of implant patients have not improved with the technology. Some patients, like Nichols, noticed significant improvements almost immediately.

“I averaged three to four seizures a week for most of my life,” she said. “Now I can go a week without any incidents. And the ones I have are shorter; less than 30 seconds. My husband noticed right away. I have a lot more confidence.”

Nichols' advice to other epileptics is to be proactive and never give up.

“Don't close your mind off to any kind of treatment,” she said. “A couple years ago, I had never heard of this, but I was always asking questions and doing research.

“Now I feel like I've got a brand new life.”

Ben Schmitt is a Trib Total Media staff writer. Reach him at 412-320-7991 or

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.